Latest news with #electroCore
Yahoo
05-05-2025
- Business
- Yahoo
electroCore completes acquisition of neurotechnology solution provider NeuroMetrix
Bioelectronic technology company electroCore has completed the acquisition of neurotechnology solution provider NeuroMetrix including its Quell platform. Last December, electroCore signed a definitive agreement to acquire NeuroMetrix (Nuro). NeuroMetrix's Quell platform is an app and cloud-enabled wearable neuromodulation solution intended to treat fibromyalgia symptoms via Quell Fibromyalgia and chronic pain through Quell 2.0. The Quell Fibromyalgia device has received authorisation from the Food and Drug Administration (FDA) and is covered by 27 US patents. It employs a custom microchip to deliver nerve stimulation in a compact form. NeuroMetrix's portfolio also includes another product, DPNCheck, a point-of-care test intended for peripheral neuropathy. DPNCheck is excluded from this deal. Last year in December, electroCore had stated in its press release that DPNCheck is expected to be divested by NeuroMetrix before the consummation of this deal. As per the terms of the merger, which was approved by NeuroMetrix's shareholders in March 2025, each share of NeuroMetrix common stock, outstanding immediately before the transaction closure, was converted into the right to receive a cash payment of $4.49 per share and one contingent value right (CVR). These CVRs provide holders with potential cash payments based on sales milestones from the Quell business and future proceeds from the sale of DPNCheck business, contingent to the terms defined in the CVR agreement dated 1 May 2025. With the acquisition, NeuroMetrix became an indirect wholly-owned electroCore subsidiary. The acquisition of NeuroMetrix's Quell Fibromyalgia Solution enhances electroCore's range of non-invasive bioelectronic therapies, broadens its commercial presence—especially within the VA Hospital System—and is anticipated to significantly expand its target market for addressing chronic pain and wellness issues. electroCore CEO Dan Goldberger said: 'With this transaction now closed, we are well-positioned to immediately leverage our established distribution channels, particularly within the VA Hospital System, to accelerate adoption of the Quell Fibromyalgia solution. 'This addition meaningfully expands our addressable market and diversifies our portfolio of non-pharmaceutical, non-invasive nerve stimulation offerings, strengthening electroCore's position as a leading publicly traded bioelectronic technology platform focused on wellness and chronic pain management.' In January 2023, NeuroMetrix launched its DPNCheck 2.0 device commercially for peripheral neuropathy detection. "electroCore completes acquisition of neurotechnology solution provider NeuroMetrix" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
16-04-2025
- Business
- Yahoo
electroCore to Participate at the Planet MicroCap Showcase
ROCKAWAY, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Planet MicroCap Showcase taking place at the Paris Hotel & Casino in Las Vegas on April 23 & 24, 2025. Dan Goldberger, CEO, will host a group presentation on Wednesday, April 23, 2025 at 1:30 p.m. PT and host one-on-one meetings throughout both days. To schedule a one-on-one meeting with Mr. Goldberger, investors are encouraged to reach out to Planet MicroCap or electroCore's investor relations at ecor@ About electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation ('nVNS') technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets. For more information, visit Contact ECOR Investor Relations(973) 302-9253investors@ in to access your portfolio
Yahoo
05-03-2025
- Business
- Yahoo
electroCore to Participate at Upcoming Investor Conferences
Management to Attend the 37th Annual Roth Conference and the LSI USA '25 ROCKAWAY, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in two upcoming investor conferences. Management will attend and engage with investors at: The 37th Annual Roth Conference March 16-18 at the Laguna Cliffs Marriott Resort & Spa in Dana Point, California. Joshua Lev, Chief Financial Officer, will host one-on-one meetings at the conference. The LSI USA '25, March 17-21 at the Waldorf Astoria Monarch Beach Resort in Dana Point, California. Joshua Lev, Chief Financial Officer, will exhibit at the conference. Investors attending these events who are interested in scheduling a meeting with management can do so by contacting their respective Roth or LSI representative, or by emailing FNK IR at ecor@ for more information. About the Roth Capital Partners ConferenceThe Annual ROTH Conference is one of the largest in the nation for small-cap companies, combining company presentations, Q&A sessions and management 1-on-1 meetings. The format provides investors the opportunity to hear from and meet with executive management from approximately 500 private and public companies in a variety of growth sectors. Roth's award-winning Research Team identifies distinguished presenting companies across broad sectors, including consumer, energy, healthcare, industrial growth, metals & mining, sustainability, services, technology and more. About LSILSI is a team of industry insiders, market analysts, media professionals, and events strategists with a shared mission to save and improve lives through innovative medical technology — in the United States, and across the globe. About electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation ('nVNS') technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets. For more information, visit Contact ECOR Investor Relations(973) 302-9253investors@ in to access your portfolio
Yahoo
30-01-2025
- Business
- Yahoo
Insider Stock Buying Reaches US$675.8k On electroCore
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in electroCore, Inc.'s (NASDAQ:ECOR) case, it's fantastic news for shareholders. Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether. Check out our latest analysis for electroCore Over the last year, we can see that the biggest insider purchase was by CEO & Director Daniel Goldberger for US$248k worth of shares, at about US$6.43 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$15.58. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive. While electroCore insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! electroCore is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying. Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that electroCore insiders own 23% of the company, worth about US$24m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment. There haven't been any insider transactions in the last three months -- that doesn't mean much. However, our analysis of transactions over the last year is heartening. Overall we don't see anything to make us think electroCore insiders are doubting the company, and they do own shares. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing electroCore. You'd be interested to know, that we found 2 warning signs for electroCore and we suggest you have a look. But note: electroCore may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
